myelodysplastic syndromes (MDS) | Page 158 | Aplastic Anemia & MDS International Foundation Return to top.

myelodysplastic syndromes (MDS)

The clinical, quality of life, and economic consequences of chronic anemia and transfusion support in patients with myelodysplastic syndromes

Author(s): 
Platzbecker U, Hofbauer LC, Ehninger G, Hölig K.
Primary Author: 
Platzbecker U
Journal Title: 
Leuk Res
Original Publication Date: 
Feb 2012

Most patients with

Bone Marrow Disease(s): 

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group

Author(s): 
Westers, Ireland, Kern, Alhan, Balleisen, Bettelheim, Burbury, Cullen, Cutler, Della Porta, Dräger, Feuillard, Font, Germing, Haase, Johansson, Kordasti, Loken, Malcovati, te Marvelde, Matarraz, Milne, Moshaver, Mufti, Ogata, Orfao, Porwit, Psarra, more
Primary Author: 
Westers TM
Journal Title: 
Leukemia
Original Publication Date: 
Feb 2012

Bone Marrow Disease(s): 

Multicentre validation of a reproducible flow cytometric score for the diagnosis of low-risk myelodysplastic syndromes: results of a European LeukemiaNET study

Author(s): 
Della Porta MG, Picone C, Pascutto C, Malcovati L, Tamura H, Handa H, Czader M, Freeman S, Vyas P, Porwit A, Saft L, Westers TM, Alhan C, Cali C, Van de Loosdrecht AA, Ogata K.
Primary Author: 
Della Porta MG
Journal Title: 
Haematologica
Original Publication Date: 
Feb 2012

Background. Current World Health Organization classification of

Bone Marrow Disease(s): 

The small population of PIG-A mutant cells in myelodysplastic syndromes do not arise from multipotent hematopoietic stem cells

Author(s): 
Pu JJ, Hu R, Mukhina GL, Carraway HE, McDevitt MA, Brodsky RA
Primary Author: 
Pu JJ
Journal Title: 
Haematologica
Original Publication Date: 
Feb 2012

Background. Patients with

Bone Marrow Disease(s): 

New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge

Primary Author: 
Schanz J
Journal Title: 
J Clin Oncol
Original Publication Date: 
Mar 2012

PURPOSE:

The karyotype is a strong independent prognostic factor in myelodysplastic syndromes (MDS). Since the implementation of the International Prognostic Scoring System (IPSS) in 1997, knowledge concerning the prognostic impact of

Bone Marrow Disease(s): 

Allogeneic Stem Cell Transplantations for elderly patients with Myelodysplastic Syndrome

Author(s): 
Kröger N
Primary Author: 
Kröger N
Journal Title: 
Blood
Original Publication Date: 
Apr 2012

Allogeneic hematopoietic stem cell transplantation is well accepted as a curative treatment approach for younger patients with myelodysplastic syndrome (MDS) and has become one of the most frequent indications for allogeneic stem cell transplantation as reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). However, MDS patients are usually elderly with a median age of about 75 years at diagnosis. Large register studies have confirmed the feasibility of the procedure in elderly MDS patients and in the register of the European

Bone Marrow Disease(s): 

Erica Warlick, MD

Warlick, Erica
Assistant Professor of Medicine
University of Minnesota Medical Center

Dr. Warlick is an Assistant Professor of Medicine in the Division of Hematology, Oncology, and Transplantation at the University of Minnesota. Her clinical and research efforts focus on the treatment of hematologic malignancies. She has particular interest in myeloid malignancies and the development of new strategies utilizing hematopoietic stem cell transplantation, traditional chemotherapeutics, as well as novel biologic modifiers to treat this diverse group of diseases.

Share with addtoany.com.